Evidence map›Paper›PMID 27139457›Full record

ReviewCurrent treatment options in oncology2016

Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.

Sujata Narayanan, A Dimitrios Colevas

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 28 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Advancements in the treatment of differentiated thyroid cancer.Therapeutic advances in endocrinology and metabolism · 2021
    Review
  15. Review
  16. Review
  17. Review
  18. Refractory thyroid carcinoma: which systemic treatment to use?Therapeutic advances in medical oncology · 2018
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sujata NarayananDivision of Medical Oncology, School of Medicine, Stanford University, Stanford, CA, 94305, USA.
A Dimitrios ColevasDivision of Medical Oncology, School of Medicine, Stanford University, Stanford, CA, 94305, USA. colevas@stanford.edu.
Stanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementRadioiodine refractory differentiated thyroid cancer (RAI-R DTC) is a challenging malignancy with limited prognosis and treatment options. Recently, clinical trials with targeted therapies have advanced the outlook of these patients, and inhibition of the vascular endothelial growth factor (VEGF) axis has led to the approval of small-molecule tyrosine kinase inhibitors (TKIs) for first-line treatment of radioiodine refractory disease. In addition to approved therapies (sorafenib and lenvatinib), other multi-targeted tyrosine kinase inhibitors that are commercially available have been recognized as viable treatment options for RAI-R DTC. Our preference is to initially use lenvatinib, given the dramatic progression-free survival (PFS) improvement versus placebo, with the caveat that 24 mg daily is not often tolerated and lower doses often used. In patients with BRAF V600E mutation, BRAF inhibitors are now considered for treatment, especially if patients are at high risk from antiangiogenic therapy. Research is continuing to evolve in identifying mechanisms related to radioiodine refractoriness, and trials are evaluating therapeutic molecules to overcome this resistance. Clinical care of patients with RAI-R DTC requires careful consideration of both patient and disease characteristics. Many patients with asymptomatic and indolent disease can be followed for years without treatment while others with high volume or rapidly progressive disease merit early intervention.

Indexed as

Molecular Targeted TherapyAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorClinical Trials as TopicCombined Modality TherapyDisease ManagementHumansIodine RadioisotopesNeoplasm GradingProtein Kinase InhibitorsRadiation ToleranceRetreatmentThyroid NeoplasmsAntineoplastic AgentsBiomarkers, TumorIodine RadioisotopesProtein Kinase InhibitorsBRAF inhibitorsMEK inhibitorsRadioiodine refractory thyroid cancerSmall-molecule tyrosine kinase inhibitors

Identifiers

PMID27139457
OpenAlexW2344317674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.